This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
—Drs Khan, Chandrasekaran, and Needle suggest that a standard one-year course of isoniazid prophylaxis would be as effective in immunocompromised patients as it is in normal hosts. In the absence of any studies comparing isoniazid effects in the two patient populations, their recommendation seems reasonable. However, I believe surveillance and controlled studies are required to clarify indications, to establish the duration of therapy, and to determine the safety of using isoniazid therapy in patients with renal failure (and other immunosuppressed hosts). Our remarks were intended to stimulate interest in resolving these issues.
Brandspigel K. Tuberculosis in Chronic Renal Failure-Reply. Arch Intern Med. 1981;141(11):1554. doi:10.1001/archinte.1981.00340120162038
Best of JAMA Network 2022
Customize your JAMA Network experience by selecting one or more topics from the list below.